Johnson & Johnson (JNJ) revenue breakdown
By segment, Innovative Medicine is the largest at 64% of fiscal 2025 revenue, growing 7% a year over 9 years.
By region, United States is the largest at 57% of fiscal 2025 revenue, growing 4% a year over 9 years.
Revenue by segment
Fiscal years, as Johnson & Johnson reports them in its 10-K filings; fiscal 2025 total $94.2B.
| Segments | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $33.5B | $36.3B | $40.7B | $42.2B | $45.2B | $51.7B | $52.6B | $54.8B | $57.0B | $60.4B | 64% |
| MedTech | $25.1B | $26.6B | $27.0B | $26.0B | $23.0B | $27.1B | $27.4B | $30.4B | $31.9B | $33.8B | 36% |
| Consumer Health | $13.3B | $13.6B | $13.9B | $13.9B | $14.4B | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Johnson & Johnson reports them in its 10-K filings; fiscal 2025 total $94.2B.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $37.8B | $39.9B | $41.9B | $42.1B | $43.1B | $40.6B | $42.0B | $46.4B | $50.3B | $53.8B | 57% |
| Europe | $15.8B | $17.1B | $18.8B | $18.5B | $19.0B | $20.6B | $20.7B | $20.4B | $20.2B | $21.5B | 23% |
| Asia-Pacific, Africa | $12.6B | $13.4B | $14.8B | $15.6B | $15.1B | $13.6B | $13.2B | $13.8B | $13.6B | $14.0B | 15% |
| Western Hemisphere excluding U.S. | $5.7B | $6.0B | $6.1B | $5.9B | $5.3B | $3.9B | $4.1B | $4.5B | $4.7B | $4.9B | 5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for JNJ.
Open JNJ in InvestinglyQuestions
Where does Johnson & Johnson make its money?
In fiscal 2025, by segment: Innovative Medicine $60.4B, MedTech $33.8B.
From Johnson & Johnson's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.